James Condulis
Stock Analyst at Stifel
(2.04)
# 2,596
Out of 5,242 analysts
12
Total ratings
41.67%
Success rate
0.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Buy | $98 → $108 | $78.06 | +38.36% | 3 | May 6, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $125 → $130 | $100.67 | +29.13% | 1 | Apr 29, 2026 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $75 | $28.47 | +163.44% | 1 | Apr 14, 2026 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $21 | $13.93 | +50.75% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Hold | $24 → $6 | $4.51 | +33.04% | 2 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $35.67 | +40.17% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $4.04 | +147.52% | 1 | Dec 5, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $32.69 | -8.23% | 1 | Jan 22, 2025 |
Cytokinetics
May 6, 2026
Maintains: Buy
Price Target: $98 → $108
Current: $78.06
Upside: +38.36%
Mirum Pharmaceuticals
Apr 29, 2026
Maintains: Buy
Price Target: $125 → $130
Current: $100.67
Upside: +29.13%
Tectonic Therapeutic
Apr 14, 2026
Initiates: Buy
Price Target: $75
Current: $28.47
Upside: +163.44%
Amylyx Pharmaceuticals
Mar 3, 2026
Initiates: Buy
Price Target: $21
Current: $13.93
Upside: +50.75%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Hold
Price Target: $24 → $6
Current: $4.51
Upside: +33.04%
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $35.67
Upside: +40.17%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $4.04
Upside: +147.52%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $32.69
Upside: -8.23%